The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Management of Chemotherapy Induced Nausea and Vomiting

항암치료 중 구역과 구토의 처치

  • Song, Kyung-Ho (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Konyang University Hospital)
  • 송경호 (건양대학교 의과대학 내과학교실)
  • Published : 2012.05.01
⟨ Previous Next ⟩

Abstract

Chemotherapy induced nausea and vomiting (CINV) is typically biphasic. The acute phase usually peaks in 5-6 hours after the administration of chemotherapeutic agents and the delayed phase can occur subsequently over 24hours after chemotherapy. Antiemetic therapy is crucial to prevent this unwanted side effect effectively, and NK1 antagonist, $5-HT_{3}$ antagonist, corticosteroid are the main player. The combination and dosing is determined by the emetogenicity of the chemotherapeutic agents to be administrated.

Keywords

References

  1. Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy- induced emesis well managed in oncological clinical practice? an observational study. Support Care Cancer 2003;11:156-161.
  2. Grunberg SM. Obstacles to the implementation of antiemetic guidelines. J Natl Compr Canc Netw 2009;7:601-605. https://doi.org/10.6004/jnccn.2009.0040
  3. Kaiser R. Antiemetic guidelines: are they being used? Lancet Oncol 2005;6:622-625. https://doi.org/10.1016/S1470-2045(05)70284-9
  4. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl 5):v232-v243. https://doi.org/10.1093/annonc/mdq194
  5. National Comprehensive Cancer Network (NCCN). Antiemesis. NCCN Guidelines 2012; Version 1. 2012 [cited 2012 April 22]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
  6. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-4198. https://doi.org/10.1200/JCO.2010.34.4614
  7. Herrstedt J, Roila F; ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2009;20 (Suppl 4):S156-S158.
  8. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-2494. https://doi.org/10.1056/NEJMra0706547
  9. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005;41:1278-1285. https://doi.org/10.1016/j.ejca.2005.01.024
  10. Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapyinduced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012 Mar 6 [Epub]. http://dx.doi.org/10.1093/annonc/mds021.
  11. Hashimoto H, Toide K, Kitamura R, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993;218:585-595. https://doi.org/10.1111/j.1432-1033.1993.tb18412.x

Cited by

  1. 항암화학요법을 받고 있는 유방암 환자에서 내관지압 방법에 따른 오심, 구토, 식욕부진의 효과 비교 vol.22, pp.2, 2012, https://doi.org/10.7586/jkbns.2020.22.2.102